IPIX could test P, B, and K with other formulas and other companies might want to test K and B and P with their formulas in their own labs to see what they could have then. The interest keeps building up after every clinical trial.
If there is a BP that wants to buy out IPIX in full, then waiting for P results make sense. We know BOM has differentail results than lead market drug. Prevents and delays. IMO, IPIX has enough data now to position themselves for a better deal. If P comes through, then the potential deal(s) are substantial.
News 
Market Data 
Discover 
AI
